MWA
BBLG

MFA Wealth Advisors’s Bone Biologics BBLG Stock Holding History

MFA Wealth Advisors’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-67
Closed -$858 – 101
2024
Q3 		$858 Hold
67
– – ﹤0.01% 459
2024
Q2 		$492 Buy
+67
New +$661 ﹤0.01% 493
2023
Q2 		– Sell
-67
Closed -$25K – 78
2023
Q1 		$25K Buy
+67
New +$28K 0.01% 70

Other funds holding BBLG

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

MFA Wealth Advisors's BBLG Position: Q4 2024 in Review

MFA Wealth Advisors sold out of Bone Biologics (BBLG) in Q4 2024, closing a stake of 67 shares — an estimated $858 sold.

MFA Wealth Advisors first reported a position in BBLG in Q1 2023 and held it in 3 quarters. The position peaked at $25K in Q1 2023. 6 funds tracked by Wall St. Rank hold BBLG as of Q4 2024.

  • MFA Wealth Advisors reported no remaining Bone Biologics position as of Q4 2024 after selling out during the quarter.
  • MFA Wealth Advisors sold 67 Bone Biologics shares in Q4 2024, an estimated $858.
  • MFA Wealth Advisors first reported a position in Bone Biologics in Q1 2023 and held it in 3 quarters.
  • MFA Wealth Advisors's Bone Biologics position peaked at $25K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Bone Biologics as of Q4 2024.

Based on MFA Wealth Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.